BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35676452)

  • 1. Guillain-Barré Syndrome Associated with COVID-19 Vaccines: A Perspective From Spontaneous Report Data.
    Atzenhoffer M; Auffret M; Pegat A; Masmoudi K; Khouri C; Bertin B; Vial T
    Clin Drug Investig; 2022 Jul; 42(7):581-592. PubMed ID: 35676452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guillain-Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis.
    Censi S; Bisaccia G; Gallina S; Tomassini V; Uncini A
    J Neurol; 2024 Mar; 271(3):1063-1071. PubMed ID: 38233678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.
    Kim JE; Park J; Min YG; Hong YH; Song TJ
    J Peripher Nerv Syst; 2022 Sep; 27(3):206-214. PubMed ID: 35751472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021.
    Woo EJ; Mba-Jonas A; Dimova RB; Alimchandani M; Zinderman CE; Nair N
    JAMA; 2021 Oct; 326(16):1606-1613. PubMed ID: 34617967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
    Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
    Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
    JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
    García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database.
    Keh RYS; Scanlon S; Datta-Nemdharry P; Donegan K; Cavanagh S; Foster M; Skelland D; Palmer J; Machado PM; Keddie S; Carr AS; Lunn MP;
    Brain; 2023 Feb; 146(2):739-748. PubMed ID: 35180300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare cases of Guillain-Barré syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021.
    Lehmann HC; Oberle D; Keller-Stanislawski B; Rieck T; Streit R
    Euro Surveill; 2023 Jun; 28(24):. PubMed ID: 37318764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of COVID-19 vaccine type on Guillain-Barré syndrome: Two cases and a literature review.
    Lee HY; Lien WC
    Hum Vaccin Immunother; 2023 Dec; 19(1):2171231. PubMed ID: 36919452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature.
    Min YG; Ju W; Ha YE; Ban JJ; Lee SA; Sung JJ; Shin JY
    J Neuroimmunol; 2021 Oct; 359():577691. PubMed ID: 34416410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase.
    Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY
    J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.
    García-Grimshaw M; Michel-Chávez A; Vera-Zertuche JM; Galnares-Olalde JA; Hernández-Vanegas LE; Figueroa-Cucurachi M; Paredes-Ceballos O; Reyes-Terán G; Carbajal-Sandoval G; Ceballos-Liceaga SE; Arauz A; Valdés-Ferrer SI
    Clin Immunol; 2021 Sep; 230():108818. PubMed ID: 34358692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study.
    Jeong HS; Chun BC
    PLoS One; 2024; 19(2):e0297902. PubMed ID: 38381729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No significant increase in Guillain-Barré syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study.
    Jaffry M; Mostafa F; Mandava K; Rosario S; Jagarlamudi Y; Jaffry K; Kornitzer J; Jedidi K; Khan H; Souayah N
    Vaccine; 2022 Sep; 40(40):5791-5797. PubMed ID: 36055875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study.
    Ha J; Park S; Kang H; Kyung T; Kim N; Kim DK; Kim H; Bae K; Song MC; Lee KJ; Lee E; Hwang BS; Youn J; Seok JM; Park K
    Sci Rep; 2023 Mar; 13(1):3773. PubMed ID: 36882454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series.
    Berrim K; Lakhoua G; Zaiem A; Charfi O; Aouinti I; Kastalli S; Daghfous R; El Aidli S
    Br J Clin Pharmacol; 2023 Feb; 89(2):574-578. PubMed ID: 36398559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
    Oo WM; Giri P; de Souza A
    J Neuroimmunol; 2021 Nov; 360():577719. PubMed ID: 34560365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1.
    Patel SU; Khurram R; Lakhani A; Quirk B
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33888484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.